ZeroStack Corp.ZSTK

ZeroStack Corp., the Nasdaq-listed entity positioning itself as the “first asset management company focused on providing exposure to decentralised AI,” also operates a global pharmaceutical distribution business through its wholly owned subsidiary. On 21 July 2026, the company filed a Schedule 13D/A showing a beneficial owner increasing its stake to 9.94%, a move that arrives just ahead of the annual meeting and the pending redomiciliation vote in Texas. The filing stops short of explaining why a stake is being bulked up while the company’s cash position sits at $2.0 million and its operating cash burn for the quarter was $3.8 million.

In the same week, ZeroStack announced it had secured purchase orders for up to approximately US$14.7 million of pharmaceutical inventory in Germany from two customers, a figure that management framed as validation for the dual-business thesis. The company’s narrative now pivots from pharma logistics to “decentralised AI exposure,” yet the 10-Q for the quarter ending 31 March 2026 still shows $7.3 million in revenue, an operating loss of $62.7 million, and a diluted EPS of minus $3.68, which is closer to venture math than to listed-market arithmetic.

The company’s most recent 10-Q (period ending 31 March 2026) reports total assets of $45.2 million against liabilities of $8.4 million, leaving stockholders’ equity at $36.8 million. Cash and cash equivalents clock in at $2.0 million, while net cash used in operating activities was minus $3.8 million. Inventory, net, stands at $1.6 million, having decreased by $269,000 in the period. Research and development expense for the quarter ending 30 June 2025 was $73,000, and the company’s diluted weighted average shares outstanding for the quarter ending 31 March 2026 is 9,958. There is no dividend, no buyback, and no stated guidance. (source: ZeroStack Corp. 10-Q (period ending 2026-03-31), https://www.sec.gov/Archives/edgar/data/1790169/000106299326003638/0001062993-26-003638-index.htm)

On 20 July 2026, ZeroStack filed an 8-K announcing the approval of a 2022 Plan Amendment to increase the number of common shares issuable from 1,506,892 to 3,006,892 and the number of incentive stock options from 847,843 to 1,695,686, an optics move that arrives while the company pursues a $107 million cryptocurrency financing announced on the same day. The financing press release notes that it eliminates a convertible note and is subject to Nasdaq and shareholder approvals-standard closing conditions that investors may now read as cautionary rather than routine. (source: ZSTK 8-K (2026-07-20), https://www.sec.gov/Archives/edgar/data/1790169/000106299326003734/form8k.htm)

ZeroStack’s identity pivot-from Flora Growth Corp. to a Nasdaq-listed “AI exposure” asset manager-is reinforced across its newsroom and social cards, yet the operational reality is captured in the 10-Q numbers rather than the brand refresh. The company’s German pharma purchase orders total $14.7 million, which is real revenue, but it sits against a backdrop of negative operating cash flow, thin liquidity, and a diluted share register that is closer to a micro-cap ledger than to a liquid Nasdaq line. The market route to clarity remains the next 10-Q and the shareholder votes on redomiciliation and share plan amendments, neither of which has been priced into the register. (source: ZeroStack Corp. news releases, https://www.zerostack.ai/invest/news-releases/2026/zerostack-corp-secures-purchase-orders-for-up-to-us-14-7-million-of-inventory-from-two-pharmaceutical-companies)

For context, ZeroStack’s market mechanism is Nasdaq-listed equity with thin liquidity and a share register that has recently expanded via a plan amendment and a cryptocurrency financing subject to customary conditions. There are no exchange-provided chart levels in the evidence set, so any depiction of price action would be speculative and outside the compliance perimeter. The filing rail remains the primary source for any next move in valuation or liquidity. (source: SEC EDGAR filings index for CIK 1790169, https://www.sec.gov/edgar/browse/?CIK=1790169)

What remains unproven is whether the $107 million cryptocurrency financing can close and whether the redomiciliation to Texas will unlock liquidity or merely relocate regulatory scrutiny. The $14.7 million in pharma orders is a real revenue line, but it does not yet offset the negative operating cash flow or the thin cash position, and the diluted share register suggests dilution risk rather than buyback capacity. The next meaningful disclosure will be the subsequent 10-Q and the shareholder votes on the redomiciliation and the amended plan, both of which are binary events for a register that is already small and liquidity-constrained. (source: ZeroStack Corp. news releases and SEC filings, https://www.zerostack.ai/invest/news-releases/2026/zerostack-announces-107-million-cryptocurrency-financing-elimination-of-convertible-note-and-plan-to-redomicile-to-texas)